Researchers turn to surprisingly simple method to combat deadly heat waves — here's how it works
Thanks to a team of researchers, 400 households in Ahmedabad are getting "cool roofs" to combat excessively high temperatures.
Ahmedabad is one of India's hottest cities, with as many as 85 days of extreme heat each year, according to CSE data shared by The Times of India.
A team from Germany's University of Heidelberg received funding from the U.K.-based Wellcome Trust — a charity dedicated to solving global health crises — for the roof project.
Wellcome Trust's grants have also funded projects to determine links between Alzheimer's and menopause and to use reverse genetics to better understand chronic conditions.
The trial in Ahmedabad aims to determine how high temperatures affect overall health. To test this, each home in the study had its roof painted with a white reflective coating, known as a "cool roof," reported Reuters. These roofs reflect the sun's rays instead of absorbing them and heating homes.
Ahmedabad is known for having extreme heat spells, with many days from April to June exceeding 100 degrees Fahrenheit, per Weather Spark.
While much of India is hot, especially during the summer months, highly populated cities like Ahmedabad tend to be more vulnerable to high temperatures. The heat island effect causes daytime temperatures to trend higher in urban areas due to heat-absorbing materials and fewer trees and water to cool things off.
Activities like burning dirty fuels and cutting down forests have sped up the rise in temperatures around the globe. These human-driven actions release large amounts of planet-warming gases such as carbon dioxide, which trap heat in the atmosphere.
Places like Ahmedabad tend to feel the effects of these activities even more than other areas. A 2018 study published in the Scientific Reports journal noted that if global temperatures rise by just 2 degrees Celsius (3.6 degrees Fahrenheit) India could see six times as many heatwaves.
Extreme heat in Ahmedabad and other regions in India has increased hospitalizations and deaths. A 2024 study published in the Dialogues in Health journaI found that extreme heat in India contributed to cardiac, skin, and vector-borne diseases in addition to hyperthermia, heat strokes, and respiratory problems.
Do you think your home has good insulation?
Definitely
It's just all right
It's good in some rooms
Not at all
Click your choice to see results and speak your mind.
The "cool roof" project is designed to help researchers understand how much of a difference a cooler environment can make on health.
Reuters reported that the project will last for one year, with researchers collecting health and environmental information from participants and non-participants to compare notes. But some residents are already noticing a difference.
"My refrigerator doesn't heat up anymore and the house feels cooler," resident Nehal Vijaybhai Bhil told Reuters. "I sleep so much better and my electricity bill is down."
By cooling down homes, Ahmedabad residents could see fewer health-related issues. And in low-income areas of the city with limited or no access to air conditioning, staying cooler without extra appliances can be life-saving.
Join our free newsletter for weekly updates on the latest innovations improving our lives and shaping our future, and don't miss this cool list of easy ways to help yourself while helping the planet.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
5 hours ago
- Business Insider
U.S. aid cuts leave $11 million in birth control supplies for Sub-Saharan Africa stranded
Millions of contraceptives intended to support women across Africa are reportedly sitting idle in warehouses and are at risk of being destroyed due to delays and funding cuts from the United States government. Millions of contraceptives intended for Africa are at risk of expiration due to U.S. government delays and funding cuts. The supplies, valued at $11 million, include various contraceptive tools meant for low-income countries. The delayed distribution may lead to increased health risks and strain on the healthcare systems in Africa. A former US official and aid worker revealed that the contraceptives, valued at around $11 million, include condoms, birth control pills, implants, and intrauterine devices (IUDs), which were originally intended to help women in low-income countries, particularly in sub-Saharan Africa, avoid unplanned pregnancies and protect themselves from sexually transmitted infections like HIV. However, the supplies are now stuck in storage facilities in Belgium and Dubai. According to sources at Reuters, the U.S. The Agency for International Development (USAID) has decided not to pay for their delivery and is no longer donating them as part of foreign aid programs. This delay stems from policy changes implemented by the former U.S. President Donald Trump, who reduced foreign assistance under his 'America First' approach: USAID gives update A recent internal memo from USAID, dated April, highlighted the urgent need to transfer the stock to prevent waste and minimize further costs. Despite this warning, a concrete plan has yet to be announced. With each passing month, the contraceptives edge closer to expiration. A senior U.S. State Department officials further confirmed that the contraceptives remain in storage, but no final decision has been made regarding their fate. The situation, according to the US official, is both frustrating and urgent for many health workers and aid groups. Another former USAID official said the stalled shipment represents nearly 20% of all contraceptives the U.S. usually donates each year, adding that if no solution is found soon, the entire stock could be destroyed, at a cost of hundreds of thousands of dollars. 'These supplies were meant to help women who have little or no access to family planning—girls fleeing conflict, mothers in refugee camps, and young women at risk of early pregnancy, ' one source said. ' The condoms in the shipment were also meant to help prevent the spread of HIV, which continues to impact millions across the region.' It added. Karen Hong, head of supply chain at the United Nations Population Fund (UNFPA), said her team is already working on an alternative plan. ' We cannot dwell on an issue for too long; when urgency and clarity don't align, we have to move on,' she said.
San Francisco Chronicle
12 hours ago
- San Francisco Chronicle
New Alzheimer's blood tests make diagnosis easier — but they're not right for everyone
The number of Americans with Alzheimer's disease, the most common cause of dementia in the U.S., is projected to rise significantly in the coming decades. The devastating disease has no cure, but the past several years have brought promising developments in new drug therapies and blood tests that help doctors treat and diagnose the disease. Here's what to know about the blood tests that diagnose Alzheimer's, one of which got full FDA approval in May. How they work Several commercially available blood tests have become available the past few years, most recently from biotech company Fujirebio Diagnostics, which got full approval from the FDA last month. Each test measures slightly different things, but overall they look for abnormal levels of certain proteins — amyloid and tau — in the blood. The accumulation of amyloid and tau proteins in the brain, often called plaques, are hallmark signs of Alzheimer's. If someone has tau plaques in the brain, for instance, some of that will leak out of the brain into the blood, resulting in a blood test result showing higher than normal levels of tau. In patients with symptoms of cognitive impairment, the tests predict an Alzheimer's diagnosis with about 90% accuracy. Why they're important The blood tests are a notable development because they are less expensive and less invasive than other types of testing that doctors have long used to diagnose patients with Alzheimer's. One is a PET scan, which involves injecting a patient with a radioactive tracer that binds to amyloid or tau in the brain so the presence of the proteins can be seen in a scan. It can cost several thousand dollars, compared to several hundred dollars for a blood test. The other is a spinal tap, which is painful or uncomfortable for many people. This method measures different forms of amyloid and tau in the spinal fluid. 'Up until these blood tests came out, a physician was stuck doing a PET scan or spinal tap, so not great options,' said Dr. Frank Longo, a professor of neurology at Stanford Medicine. 'The big breakthrough is finding something to measure in the blood that's about 90% accurate of what's going on in the brain, about as accurate as spinal fluid or a PET scan.' Doctors use the blood test as part of a broader medical evaluation that also includes a patient history, neurological exam and other testing. The blood test can help rule out Alzheimer's as the cause of a patient's cognitive impairment and potentially avoid unnecessary further testing. If someone's blood test comes back normal, for example, they may not have to undergo the PET scan or spinal tap, and their doctor can look into other potential causes of the cognitive impairment. 'That's the biggest practical thing it's doing now,' Longo said. It's important to distinguish Alzheimer's from other types of dementia because there are Alzheimer's treatments that have come out the last few years that help slow the progression of Alzheimer's. But patients must be in relatively early stages of the disease, with mild impairment or mild dementia, to be eligible. Some of the therapies have significant side effects, so patients would not want to start them unless they knew it was Alzheimer's, and not something else, causing the dementia. They're not for everyone The tests are approved only for people who already have symptoms of cognitive impairment and are of a certain age — 55 and over or 60 and over, depending on the test. They are not approved for healthy adults with normal cognition who want to diagnose or rule out Alzheimer's, or who are simply curious if they are at risk for developing Alzheimer's. They must be ordered by a doctor. They're becoming more common, but may not be covered by insurance Some of the blood tests have been available for a year or two, Longo said, but they were under an earlier and more limited type of FDA approval, not the full approval that the agency granted last month to the Fujirebio test. So they are poised to become more common. 'A year ago, most of my colleagues and I were not ordering these,' Longo said. 'I'd say less than 5% or 10% of the time we were ordering these. Now people are starting to order them in symptomatic patients. It's not rare now. They're starting to be recognized more.' Some primary care doctors are starting to order the tests as well, said Dr. Armen Moughamian, medical director of Sutter Health's Ray Dolby Brain Center at CPMC in San Francisco. The center treats patients with memory disorders. 'It's definitely a minority, but I've been seeing it done,' he said. As with many new medical tests, insurers may not cover them yet, but that usually evolves over time. Full FDA approval may help make the case for the tests to be covered, Longo said. 'There is some uncertainty and lack of clarity about whether insurance and Medicare pay,' Moughamian said. 'That creates some hesitancy for providers to order it.' They may one day be used to screen and diagnose healthy people earlier In people with Alzheimer's, amyloid plaques begin to form in the brain as many as 20 years before they show symptoms. Right now, newer therapies for Alzheimer's — like lecanemab and donanemab, which slow the progression of the disease — are approved only for people with symptoms. Those symptoms are mild cognitive impairment or mild dementia, the early stages of symptomatic Alzheimer's. This means people who have not yet developed symptoms, but who have amyloid plaques in the brain, cannot get these treatments. So if a blood test could be used in pre-symptomatic people, it could mean better screening and earlier diagnosis to larger groups of people. 'What we want to push for is earlier diagnosis because new therapies are available when we catch people in earlier stages,' Moughamian said. Moughamian is leading two clinical trials that examine whether drugs that remove amyloid in the brain, donanemab and another drug remternetug, can work in people who have amyloid plaques but have not yet developed symptoms. They are using an Alzheimer's blood test to see whether patients are eligible for the trial.
Chicago Tribune
13 hours ago
- Chicago Tribune
Jim Taylor: What my wife's experience with Alzheimer's has taught me
After several unexplained memory slips, there came a day when my wife, Geri, didn't recognize her own face in the mirror. That's when we knew it was time for her to get checked out. It was 2012, and Alzheimer's was a feared diagnosis. At the time, billions of dollars of investments into research and development had failed to produce treatments that could prevent, slow or cure the disease. Getting a definitive diagnosis would be extremely difficult, but the alternative was living with years of the landscape for Alzheimer's diagnosis and treatment has taken a great leap forward. It is increasingly possible to manage the disease and live a fulfilling life. We have reached a historic moment with the FDA's approval of the first blood biomarker tests for Alzheimer's. This long-awaited breakthrough means physicians can now detect early signs of Alzheimer's — which accounts for 70% of all cases of dementia — using a simple blood test that can be done during a regular check-up with your PET scans remain important for confirming a diagnosis, they are only available at specialized centers, typically in urban medical centers, and they are expensive. Blood biomarker tests now offer an easy first step in the diagnostic journey. They provide fast answers for people experiencing memory problems and can even spot early signs of cognitive decline years before symptoms appear. Without these tests, most people have a long, challenging path to wife Geri's path to diagnosis was anything but simple. In 2012, a neurologist confirmed she had mild cognitive impairment, a common precursor to Alzheimer's. It was a life-altering event. Over the next few years, we knew we had to dig deeper into the cause of her condition, to uncover any potential medical options. Eventually we found a clinical trial for an experimental Alzheimer's drug, and she received a PET scan to determine whether she qualified for the trial. Her brain scan detected amyloid plaque, the telltale sign of Alzheimer's. The diagnosis was difficult to face, but it meant we didn't have to struggle with uncertainty. We could act.I understand the fear that surrounds an Alzheimer's diagnosis, but catching it early helps. Changes in the brain begin years before memory problems become noticeable. The earlier the diagnosis, the more options people have. Research shows that anti-amyloid therapies are more effective when administered earlier: In one clinical trial, patients with early Alzheimer's showed 35% slowing of cognitive decline, compared with those on the placebo. These treatments can help people maintain their independence longer and make the most of their lucid was fortunate to participate in a clinical trial that significantly slowed her disease progression. The seven-year trial period was a game-changer for us. The regular infusions were a source of hope as we saw her benefit from the medication. This precious time allowed Geri to develop coping strategies to manage her disease. Together, we traveled across the country giving talks about living with Alzheimer's disease, and Geri needed very little assistance. We cherished this time together — years made possible because we sought answers early. Following the FDA's landmark approval of blood biomarker tests, the next step is making these tests widely available. Hospitals and health care systems across the country should ensure primary care physicians are aware of these tests and understand how to use them. Public education campaigns can raise awareness with people who have concerns about cognitive impairment and their detection gives people meaningful choices, and most importantly it gives people time. Time to benefit from lifestyle changes, participate in groundbreaking clinical trials, and access treatments when they can make the greatest difference. Although facing a potential Alzheimer's diagnosis is daunting, waiting only limits a person's options. If you're concerned that you or a loved one might have signs of cognitive impairment, please don't stay in the dark. Blood biomarker tests offer real hope in a new era of Alzheimer's care. The sooner we embrace these advances, the more precious time we can preserve.
